As Cipla prepares to celebrate its 90th anniversary next month, Chairman Y.K. Hamied expressed a firm resolve to continue the company’s legacy of delivering affordable and high-quality medicines in India and across global markets.
A Legacy of Service and Innovation
Addressing shareholders at Cipla’s 89th Annual General Meeting, Hamied reflected on his six-decade journey with the company. “The 65 years that I have spent actively in Cipla since 1960 have been the most rewarding experience,” he noted. He emphasized that Cipla has remained among the leading generic pharmaceutical companies, not just in India but also in key international markets such as Africa, the USA, and Europe, with its footprint steadily expanding across the globe.
Looking ahead, he said Cipla would focus on critical therapeutic areas including respiratory, cardiac, cancer, obesity, mental health, and anti-microbial resistance.
Expanding Palliative Care Services
As reported by Hindu Business Line, Hamied also highlighted Cipla’s impact in palliative care. Since launching its Palliative Care and Training Centre in Pune in 1997, the initiative has supported more than 25,000 patients and their families. Over the years, Cipla has expanded these services to over 30 cities across India, furthering its commitment to compassionate care.
Strengthening Supply Chain and Diversified Portfolio
Responding to shareholder queries, Cipla Managing Director and Global CEO Umang Vohra reassured stakeholders about the company’s readiness to withstand potential external challenges, such as proposed US tariffs. He pointed out that Cipla operates a diversified manufacturing and supply chain across the US, India, and other global regions, which reduces geographic risk.
Driving Growth Through Science and Technology
Vohra outlined Cipla’s continued investment in high-potential segments such as biosimilars, mRNA platforms, and next-generation diabetes and obesity treatments—including GLP-1 products. He noted that Cipla plans to invest around ₹2,000 crore annually in capacity expansion, funded entirely through internal accruals.
In the last fiscal year, Cipla achieved its highest-ever revenue of ₹27,548 crore and currently holds ₹10,000 crore in cash reserves. Vohra affirmed that this capital would be strategically deployed to strengthen its scientific and research platforms.
Upholding Global Quality Standards
Cipla continues to operate across prescription, generics, and consumer healthcare segments. Vohra also emphasized the company’s focus on regulatory compliance, reporting that Cipla’s facilities had undergone nearly 100 audits globally, most of which yielded satisfactory results.
As the company approaches its 90th year, both leadership and legacy remain aligned in their vision—making quality healthcare accessible, sustainable, and future-ready.